New therapeutic prospect for preeclampsia

Biology
Health

Preeclampsia is a condition that affects the placenta during pregnancy and is dangerous for both the fetus and the mother. Scientists from the Institut Pasteur, Inserm and the CNRS have proposed a new therapy, tested in two rodent models, that corrects the defects identified in placental cells, and restores placental and fetal weight. The treatment successfully lowers blood pressure in the mother and resolves the characteristic preeclampsia symptoms of excess protein in urine and cardiovascular abnormalities. The research was published on July 30 in the journal Redox Biology.

Bibliography

Increased NOS coupling by the metabolite tetrahydrobiopterin (BH4) reduces preeclampsia/IUGR consequences. Laurent Chatre, Aurélien Ducat, Frank T. Spradley, Ana C. Palei, Christiane Chéreau, Betty Couderc, Kamryn C. Thomas, Anna R. Wilson, Lorena M. Amaral, Irène Gaillard, Céline Méhats, Isabelle Lagoutte, Sébastien Jacques, Francisco Miralles, Frédéric Batteux, Joey P. Granger, Miria Ricchetti and Daniel Vaiman, Redox Biology, 30 juillet 2022 DOI https://doi.org/10.1016/j.redox.2022.102406 

Contact

Myriam Rebeyrotte
Relations presse de l'Institut Pasteur
Aurélie Perthuison
Service de presse - Institut Pasteur
CNRS Press Office